免疫・アレルギー疾患政策研究事業
（○：委員長）
| ○ | 市村恵一 | 自治医科大学名誉教授 東京みみ・はな・のどサージクリニック名誉院長 |
|
| 耳鼻咽喉科 | |||
| ＜研究論文例＞ Mechanism of nasal obstruction in patients with allergic rhinitis. Ichimura K Clin Exper Allergy Rev, 2010．10:20-27. |
|||
| ＜著作例＞ 新耳鼻咽喉科学 改訂12版 加我君孝編集：市村恵一他共著,南山堂.（2022）） |
|||
| ＜著作例＞ Japanese Society of Allergology.：Japanese guidelines for allergic rhinitis 2020. Okubo K, Kurono Y, Ichimura K, et al.; Allergol Int. 2020;69(3):331-345. |
|||
| 興梠 博次 | 社会保険大牟田天領病院・病院長 | ||
| 呼吸器内科学 | |||
| CD8 and CD103 are highly expressed in asthmatic bronchial intraepithelial lymphocytes, I Hirosako S, Goto E, Tsumori K, Fujii K, Hirata N, Ando M, Kohrogi H. Int Arch Allergy Immunol 2010, 153:157-165. | |||
| T cells of atopic asthmatics preferentially infiltrate into human bronchial xenografts in SCID mice, Tsumori K, Kohrogi H, Goto E, Hirata N, Hirosako S, Fujii K, Ando M, Kawano O, Mizuta H: J Immunol 2003, 170:5712-5718. | |||
| Allergen exposure induces the expression of endothelial adhesion molecules in passively sensitized human bronchus: time course and the role of cytokines, Hirata N, Kohrogi H, Iwagoe H, Goto E, Hamamoto J, Fujii K, Yamaguchi T, Kawano O, Ando M. Am J Respir Cell Mol Biol 1998, 18:12-20. | |||
| 桑名 正隆 | 日本医科大学大学院医学研究科 大学院教授 | ||
| アレルギー膠原病内科学分野 | |||
| ＜研究論文＞ Kuwana M, Abe K, Kinoshita K, Matsubara H, Minatsuki S, Murohara T, Sakao S, Shirai Y, Tahara N, Tsujino I, Takahashi K, Kanda S, and Ogo T. Efficacy, safety and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension. Pulm. Circ. 2023; 13: e12198. doi.org/10.1002/pul2.12198 |
|||
| ＜研究論文＞ Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, Tomiyama Y, and R788-1301 Investigators. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study. Br. J. Haematol. 2023; 200(6): 802-811. doi.org/10.1111/bjh.18582 PMID: 36470677 |
|||
| ＜研究論文＞ Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 trial in diffuse cutaneous systemic sclerosis Arthritis Rheumatol. doi: 10.1002/art.42510. Online ahead of print. PMID: 37098795 |
|||
| 竹内 勤 | 埼玉医科大学 学長・慶應義塾大学 名誉教授 | ||
| リウマチ・膠原病学、臨床免疫学 | |||
| Takeuchi T, Kawanishi M, Nakanishi M, Yamasaki H, and Tanaka Y. Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial). Arthritis and Rheum, 74:1176-85, 2022. | |||
| Smolen JS, Landewe R, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich KL, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J,15 Buch MH, Burmester G,1 Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, Aoufy KE, Finckh A, Fonseca J, Gottenberg J-E, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poor G, Rubbert-Roth A, Rivellese F, Ristic GG, Stoilov N, Schulze-Koops H, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vlieland TV, Westhovens R, and van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2022 update. Ann Rheum Dis, 82:3-18, 2023. | |||
| Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo C-F, Shin K, Hirata S, Okano Y, Yasuoka H, Kuwana M, Ishii T, Kameda H, Kojima T, Taninaga T, Mori M, Miyagishi H, Sato Y, Tsai W-C, Takeuchi T, Kaneko Y, and MIRACLE study collaborators. Reduced versus maximum tolerated methotrexate dose concomitant with tumor necrosis factor inhibitor in patients with rheumatoid arthritis (MIRACLE): a randomized, open-label, non-inferiority trial. Lancet Rheum, 5:e215-24, 2023. | |||
